BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 15221999)

  • 1. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V; Arrigo C; Righi M
    Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
    Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP
    J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
    Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
    Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
    Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
    Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.
    Omuro AM; Taillandier L; Chinot O; Carnin C; Barrie M; Hoang-Xuan K
    J Neurooncol; 2007 Nov; 85(2):207-11. PubMed ID: 17896079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
    J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET
    Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract]   [Full Text] [Related]  

  • 12. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
    Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.
    Pulczynski EJ; Kuittinen O; Erlanson M; Hagberg H; Fosså A; Eriksson M; Nordstrøm M; Østenstad B; Fluge Ø; Leppä S; Fiirgaard B; Bersvendsen H; Fagerli UM
    Haematologica; 2015 Apr; 100(4):534-40. PubMed ID: 25480497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.
    Wang XX; Huang HQ; Bai B; Cai QQ; Cai QC; Gao Y; Xia YF; Xia ZJ; Jiang WQ
    Leuk Lymphoma; 2014 Nov; 55(11):2497-501. PubMed ID: 24605911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
    Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma.
    Masaki Y; Miki M; Sun Y; Nakamura T; Iwao H; Nakajima A; Kurose N; Sakai T; Jin ZX; Sawaki T; Kawanami T; Fujita Y; Tanaka M; Fukushima T; Hirose Y; Umehara H
    Int J Hematol; 2011 Jun; 93(6):720-726. PubMed ID: 21573892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.